deferiprone has been researched along with Parkinson Disease in 9 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Wilkinson, KA | 1 |
| Guo, C | 1 |
| Devos, D | 6 |
| Labreuche, J | 3 |
| Rascol, O | 3 |
| Corvol, JC | 4 |
| Duhamel, A | 4 |
| Guyon Delannoy, P | 3 |
| Poewe, W | 3 |
| Compta, Y | 3 |
| Pavese, N | 3 |
| Růžička, E | 3 |
| Dušek, P | 3 |
| Post, B | 3 |
| Bloem, BR | 3 |
| Berg, D | 3 |
| Maetzler, W | 3 |
| Otto, M | 3 |
| Habert, MO | 3 |
| Lehericy, S | 3 |
| Ferreira, J | 3 |
| Dodel, R | 3 |
| Tranchant, C | 3 |
| Eusebio, A | 3 |
| Thobois, S | 3 |
| Marques, AR | 3 |
| Meissner, WG | 3 |
| Ory-Magne, F | 3 |
| Walter, U | 3 |
| de Bie, RMA | 3 |
| Gago, M | 3 |
| Vilas, D | 3 |
| Kulisevsky, J | 3 |
| Januario, C | 3 |
| Coelho, MVS | 3 |
| Behnke, S | 3 |
| Worth, P | 3 |
| Seppi, K | 3 |
| Ouk, T | 3 |
| Potey, C | 3 |
| Leclercq, C | 3 |
| Viard, R | 3 |
| Kuchcinski, G | 3 |
| Lopes, R | 3 |
| Pruvo, JP | 3 |
| Pigny, P | 3 |
| Garçon, G | 5 |
| Simonin, O | 3 |
| Carpentier, J | 3 |
| Rolland, AS | 4 |
| Nyholm, D | 3 |
| Scherfler, C | 3 |
| Mangin, JF | 3 |
| Chupin, M | 3 |
| Bordet, R | 5 |
| Dexter, DT | 4 |
| Fradette, C | 3 |
| Spino, M | 4 |
| Tricta, F | 4 |
| Ayton, S | 4 |
| Bush, AI | 4 |
| Devedjian, JC | 6 |
| Duce, JA | 5 |
| Cabantchik, I | 3 |
| Defebvre, L | 5 |
| Deplanque, D | 3 |
| Moreau, C | 6 |
| Cabantchik, ZI | 2 |
| Danel, V | 1 |
| Mahoney-Sanchez, L | 1 |
| Bouchaoui, H | 1 |
| Gouel, F | 1 |
| Zhang, Q | 1 |
| Feng, S | 1 |
| Zhao, Y | 1 |
| Jin, B | 1 |
| Peng, R | 1 |
| Martin-Bastida, A | 1 |
| Ward, RJ | 1 |
| Newbould, R | 1 |
| Piccini, P | 1 |
| Sharp, D | 1 |
| Kabba, C | 1 |
| Patel, MC | 1 |
| Connelly, J | 1 |
| Crichton, RR | 1 |
| Sun, Y | 1 |
| Pham, AN | 1 |
| Waite, TD | 1 |
| Lei, P | 1 |
| Wong, BX | 1 |
| Sedjahtera, A | 1 |
| Adlard, PA | 1 |
| Finkelstein, DI | 1 |
| Kluza, J | 1 |
| Petrault, M | 1 |
| Laloux, C | 1 |
| Jonneaux, A | 1 |
| Ryckewaert, G | 1 |
| Rouaix, N | 1 |
| Jissendi, P | 1 |
| Dujardin, K | 1 |
| Auger, F | 1 |
| Ravasi, L | 1 |
| Hopes, L | 1 |
| Grolez, G | 2 |
| Firdaus, W | 1 |
| Sablonnière, B | 2 |
| Strubi-Vuillaume, I | 1 |
| Zahr, N | 1 |
| Destée, A | 1 |
| Pöltl, D | 1 |
| Leist, M | 1 |
| Rose, C | 1 |
| Marchetti, P | 1 |
| Meguig, S | 1 |
| Gelé, P | 1 |
| Delmaire, C | 1 |
| Cabantchik, IZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease[NCT01539837] | Phase 2 | 22 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease[NCT00943748] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease, modify regional brain mineralization (iron concentration) as assessed with T2* MRI in PD patients in the dentate nucleus. In previous animal studies, Deferiprone treatment reduced dentate nucleus iron content, as assessed by MRI. An increase in the T2*MRI value represents an increase in mineralization. (NCT01539837)
Timeframe: 6 months
| Intervention | ms (Mean) |
|---|---|
| Placebo | 30.74 |
| Deferiprone 20mg | 30.59 |
| Deferiprone 30mg | 29.86 |
To assess whether there were any serious adverse events in 6-month treatment with Deferiprone. (NCT01539837)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Deferiprone 20mg | 0 |
| Deferiprone 30mg | 0 |
1 review available for deferiprone and Parkinson Disease
| Article | Year |
|---|---|
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Chelation Therapy; Deferiprone; Humans; Iron; Iron Chelating | 2020 |
4 trials available for deferiprone and Parkinson Disease
| Article | Year |
|---|---|
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Trial of Deferiprone in Parkinson's Disease.
Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression | 2022 |
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.
Topics: Aged; Brain; Brain Chemistry; Deferiprone; Double-Blind Method; Female; Humans; Inflammation; Iron; | 2017 |
Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Topics: Animals; Cell Line; Combined Modality Therapy; Deferiprone; Disease Models, Animal; Double-Blind Met | 2014 |
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.
Topics: Aged; Ceruloplasmin; Chelation Therapy; Clinical Protocols; Deferiprone; Female; Humans; Iron; Iron | 2015 |
4 other studies available for deferiprone and Parkinson Disease
| Article | Year |
|---|---|
Iron chelation promotes mitophagy through SENP3-mediated deSUMOylation of FIS1.
Topics: Autophagy; Cysteine Endopeptidases; Deferiprone; Humans; Iron Chelating Agents; Membrane Proteins; M | 2022 |
Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.
Topics: Animals; Calcium; Cell Survival; Deferiprone; Drug Design; Hydrogen Peroxide; Iron Chelating Agents; | 2021 |
Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
Topics: Animals; Deferiprone; Disease Models, Animal; Dopamine; Iron; Iron Chelating Agents; Oxidative Stres | 2018 |
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Case-Control Studies; Ceruloplasmin; De | 2013 |